The Asco Post

Today in Oncology

Current News from the World of Oncology Last Updated: Tuesday, June 30, 2015 3:09:08 PM

Featured Columnists

Considering Clonality in Precision Medicine Michael Green, PhD  

Clinical Trials, Drug Costs, and Restoring the Primacy of the Patient Volunteer Laurence H. Baker  

Illumination and Innovation: Transforming Data Into Learning Peter P. Yu, MD, FASCO  

More Featured Columnists

Expert Opinions

ASCO Releases Details of Its Conceptual Framework for Assessing Value in Cancer Care Lowell E. Schnipper, MD  

Deciphering the Genetic Variability of Cancer to Advance Precision Oncology Care David B. Solit, MD  

Redefining Cancer Patrick Soon-Shiong, MD, FRCS(C), FACS  

More Expert Opinions

Meeting News

Elective Neck Dissection Beats Watch and Wait Approach in Early Oral Cance... Single-Agent Daratumumab Activity Deemed Remarkable in Refractory Multiple... Palbociclib Slows Progression of Hormone Receptor-Positive Breast Cancer Routine Resection of Cavity Shave Margins Halved Reexcision Rates in Breas... More Meeting News

Journal Spotlight

Meta-analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormo... Long-Term Survival Advantage Seen With Intraperitoneal vs Intravenous Chem... Outcomes of the CUSTOM Basket Trial of Molecular Profiling and Targeted Th... Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma Pro... More Journal Spotlights

Health-Care Policy

ASCO, ACCC Respond to Repeal of Medicare Sustainable Growth Rate Formula Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead After Decades of Uncertainty, the Sustainable Growth Rate Formula Is Repealed by Congress Creating a Collective Path Forward to Optimize Value in Cancer Care More Health-care Policy

Drugs & Regimens

Eribulin Improves Overall Survival in Difficult-to-Treat Sarcoma Types Ibrutinib Plus Bendamustine/Rituximab Called a New Standard in Patients With Previously Treated CLL Adjuvant Chemotherapy Proves Effective in Localized, High-Risk Prostate Cancer Single-Agent Daratumumab Activity Deemed ‘Remarkable’ in Refractory Multiple Myeloma More Drugs & Regimens

Oncology Worldwide

Noncommunicable Diseases Are the Leading Cause of Death in Low- and Middle-Income Countries How the International Innovation Grant Is Improving Cancer Care for Women in Myanmar Global Oncology Launches Global Cancer Project Map With NCI Addressing the Global Cancer Burden More Oncology Worldwide

Patient's Corner

Carpe Diem Cancer Will Always Be Part of My Life Living With a Rare Cancer—My Dr. Seuss World Cancer Has Left an Indelible Mark on Me More Patient's Corner

More on Twitter